211 related articles for article (PubMed ID: 16867031)
21. A 2-year open-label study of galantamine therapy in Chinese Alzheimer's disease patients in Hong Kong.
Chu LW; Yik PY; Mok W; Chung CP
Int J Clin Pract; 2007 Mar; 61(3):403-10. PubMed ID: 17313606
[TBL] [Abstract][Full Text] [Related]
22. A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer's disease.
Hart DJ; Craig D; Compton SA; Critchlow S; Kerrigan BM; McIlroy SP; Passmore AP
Int J Geriatr Psychiatry; 2003 Nov; 18(11):1037-42. PubMed ID: 14618556
[TBL] [Abstract][Full Text] [Related]
23. Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia.
Suh GH; Greenspan AJ; Choi SK
Int J Geriatr Psychiatry; 2006 Jul; 21(7):654-60. PubMed ID: 16821257
[TBL] [Abstract][Full Text] [Related]
24. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.
Freund-Levi Y; Basun H; Cederholm T; Faxén-Irving G; Garlind A; Grut M; Vedin I; Palmblad J; Wahlund LO; Eriksdotter-Jönhagen M
Int J Geriatr Psychiatry; 2008 Feb; 23(2):161-9. PubMed ID: 17582225
[TBL] [Abstract][Full Text] [Related]
25. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
[TBL] [Abstract][Full Text] [Related]
26. Donepezil preserves cognition and global function in patients with severe Alzheimer disease.
Black SE; Doody R; Li H; McRae T; Jambor KM; Xu Y; Sun Y; Perdomo CA; Richardson S
Neurology; 2007 Jul; 69(5):459-69. PubMed ID: 17664405
[TBL] [Abstract][Full Text] [Related]
27. [Impact of music therapy on anxiety and depression for patients with Alzheimer's disease and on the burden felt by the main caregiver (feasibility study)].
Guetin S; Portet F; Picot MC; Defez C; Pose C; Blayac JP; Touchon J
Encephale; 2009 Feb; 35(1):57-65. PubMed ID: 19250995
[TBL] [Abstract][Full Text] [Related]
28. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease.
Herrmann N; Lanctôt KL; Rothenburg LS; Eryavec G
Dement Geriatr Cogn Disord; 2007; 23(2):116-9. PubMed ID: 17148938
[TBL] [Abstract][Full Text] [Related]
29. [Characterisation and prevalence of the psychological and behavioural symptoms in patients with dementia].
López-Pousa S; Vilalta-Franch J; Garre-Olmo J; Pons S; Cucurella MG
Rev Neurol; 2007 Dec 1-15; 45(11):683-8. PubMed ID: 18050101
[TBL] [Abstract][Full Text] [Related]
30. Negative symptoms in Alzheimer's disease: a confirmatory factor analysis.
de Jonghe JF; Goedhart AW; Ooms ME; Kat MG; Kalisvaart KJ; van Ewijk WM; Ribbe MW
Int J Geriatr Psychiatry; 2003 Aug; 18(8):748-53. PubMed ID: 12891644
[TBL] [Abstract][Full Text] [Related]
31. Beneficial effects of perospirone on aggressive behavior associated with dementia.
Sato S; Mizukami K; Moro K; Tanaka Y; Asada T
Psychiatry Clin Neurosci; 2006 Feb; 60(1):106-9. PubMed ID: 16472367
[TBL] [Abstract][Full Text] [Related]
32. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics.
Gleason RP; Schneider LS
J Clin Psychiatry; 1990 Mar; 51(3):115-8. PubMed ID: 1968457
[TBL] [Abstract][Full Text] [Related]
33. [Validity and reliability of the Japanese Version of the Neuropsychiatric Inventory-Nursing Home Version (NPI-NH)].
Shigenobu K; Hirono N; Tabushi K; Ikeda M
Brain Nerve; 2008 Dec; 60(12):1463-9. PubMed ID: 19110758
[TBL] [Abstract][Full Text] [Related]
34. Confabulations in remembering past and planning future are associated with psychiatric symptoms in Alzheimer's disease.
Lee E; Akanuma K; Meguro M; Ishii H; Yamaguchi S; Meguro K
Arch Clin Neuropsychol; 2007 Nov; 22(8):949-56. PubMed ID: 17913452
[TBL] [Abstract][Full Text] [Related]
35. One-year longitudinal evaluation of neuropsychiatric symptoms in Alzheimer's disease. The REAL.FR Study.
Benoit M; Robert PH; Staccini P; Brocker P; Guerin O; Lechowski L; Vellas B;
J Nutr Health Aging; 2005; 9(2):95-9. PubMed ID: 15791352
[TBL] [Abstract][Full Text] [Related]
36. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
[TBL] [Abstract][Full Text] [Related]
37. Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia.
Sommer OH; Aga O; Cvancarova M; Olsen IC; Selbaek G; Engedal K
Dement Geriatr Cogn Disord; 2009; 27(2):155-63. PubMed ID: 19182483
[TBL] [Abstract][Full Text] [Related]
38. AMPA potentiator treatment of cognitive deficits in Alzheimer disease.
Chappell AS; Gonzales C; Williams J; Witte MM; Mohs RC; Sperling R
Neurology; 2007 Mar; 68(13):1008-12. PubMed ID: 17389305
[TBL] [Abstract][Full Text] [Related]
39. Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients.
Ferris S; Ihl R; Robert P; Winblad B; Gatz G; Tennigkeit F; Gauthier S
Alzheimers Dement; 2009 Sep; 5(5):369-74. PubMed ID: 19751915
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
Burns A; Gauthier S; Perdomo C
Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
